Horizon Discovery, a life science spin-out of Cambridge University, signs its second collaboration with pharmaceutical firm AstraZeneca.

Horizon Discovery has partnered with AstraZeneca to explore a range of oncology-relevant genotypes, marking its second collaboration with the pharmaceutical firm.

The deal is worth up to $88m in milestone payments to the Cambridge University spin-out, which will also receive an undisclosed payment up front.

The announcement builds on a strong 2013 for the company, which won the Licencing Deal of the Year at the 2013 SCRIP Intelligence Awards for its first collaboration with AstraZeneca and also closed a

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?